Project: Personalized Clinical Management of Endometrial Cancer using Liquid Biopsy, Genomics and Artificial Intelligence
| Acronym | ECLAI (Reference Number: ERAPERMED2021-076) |
| Duration | 01/02/2022 - 01/02/2025 |
| Project Topic | In the era of precision oncology, personalized management represents a challenge in Endometrial Cancer (EC). The incidence of this cancer has increased in last years, and although patient prognosis is favorable in early stages, the prognostic and therapeutic options for advanced disease are still poor or few. This has a dramatic negative effect on the overall survival of EC patients with advanced disease. Thus, to improve the personalized treatment of poor prognosis EC patients, it is necessary, on the one hand, to deep in the cancer molecular biology but, on the other, to also capture the innate intratumor heterogeneity (ITH) of these tumors. Taken together, the objective of the present proposal is to reach personalized EC management by developing new tools that recapitulate the heterogeneous molecular composition of tumors and establish new and effective therapeutic regimens. In order to address these challenges, our consortium proposes to develop a new and robust algorithm, named ECLAI, to predict recurrence and the therapy response in high-risk EC. Furthermore, we will also look for the best therapeutic options to advance in the personalized treatment of these patients. For this, the consortium will combine: a) the use of non-invasive biopsies, which capture ITH, to study the genomic landscape and to monitor the disease evolution of EC, b) the generation of valuable preclinical models to test alternative targeted therapies and c) the application of machine learning strategies to decipher a recurrence and therapeutic response rate algorithm with clinical application. This workflow will be applied with the advisory and support of patients’ associations and ENITEC, the European research network on EC. All together, this pioneering strategy has the final goal to improve the management and life quality of EC patients who currently have limited clinical opportunities. |
| Network | ERA PerMed |
| Call | 4th Joint Transnational Call for Proposals (2021) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Consorcio Centro de Investigación Biomedica en red M.P (CIBER) | Coordinator | Spain |
| 2 | Medical University of Lublin | Partner | Poland |
| 3 | Universitetet I Bergen | Partner | Norway |
| 4 | Tervisetehnoloogiate Arenduskeskus AS (Competence Centre on Health Technologies, CCHT) | Partner | Estonia |